Twentieth Mobetron System Ordered Worldwide

SUNNYVALE, Calif. (BUSINESS WIRE) August 8, 2006 IntraOp Medical Corporation (OTCBB: IOPM) has received an order from Westeinde Hospital in The Hague, Holland, for its Mobetron® system, the Company's proprietary mobile electron-beam accelerator. The system is designed exclusively for intraoperative electron radiation therapy (IOERT), which is the direct application of radiation to a tumor while a patient is undergoing cancer surgery.

Westeinde Hospital requested expedited delivery of the system to begin its IOERT program before the end of 2006. This was the second Mobetron order from a Dutch hospital, and the 20th worldwide. In the United States, Mobetrons are being used to treat cancer patients at such major medical centers as the Mayo Clinic, the University of California at San Francisco, the University of North Carolina and others.

"The sale of our Mobetron system to Westeinde Hospital further indicates that IOERT is becoming a readily accepted part of the cancer treatment regimen in Europe," said Donald A. Goer, President and Chief Executive Officer of IntraOp. "It also strengthens our position worldwide as the only vendor able to deliver a mobile, self-shielded IOERT solution."

About Westeinde Hospital Westeinde Hospital in The Hague is one of eighteen comprehensive cancer centers in the Netherlands that provide cancer treatment to the 12 million people in the Netherlands. It will be the second center that offers intraoperative electron beam treatment for cancer patients in the Netherlands.

About Intraop

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

Forward-looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.